Piramal Pharma’s Piramal Critical Care (PCC) business, a producer of Inhaled Anesthetics and a global player in hospital generics, today announced the appointment of Jeffrey Hampton as President & Chief Operating Officer (COO), the company said in an exchange filing on Tuesday

Piramal Pharma’s Piramal Critical Care (PCC) business, a producer of Inhaled Anesthetics and a global player in hospital generics, today announced the appointment of Jeffrey Hampton as President & Chief Operating Officer (COO), the company said in an exchange filing on Tuesday.

For his new role, Hampton will be based in the United States. A Bachelor of Science in Marketing from the University of Florida, Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm’s growth strategy. 

Prior to that, he was the Senior Vice President and General Manager at Apotex for the US and Latin America regions. At Apotex, Hampton restructured the US commercial team to maximize efficiency and established procedures for identifying and executing life cycle management practices to improve profitability and market penetration. 

His career, so far, spans over three decades across sales and marketing, regulatory, commercial operations, sales strategy, distribution, and business development. Hampton has also worked with several leading pharmaceutical companies, including Osmotica Pharmaceuticals, Dabur Pharma and IVAX Pharmaceuticals. 

Peter DeYoung, CEO, Global Pharma, Piramal Pharma Limited, said, “I welcome Jeff to Piramal Critical Care and wish him all the success in his new role. His experience across the domains of sales and marketing will help us develop stronger, long-term global operations strategies to deliver profitable growth.” 

Hampton said, “It is truly an honour to be joining such a fast-paced, growth-oriented global company like Piramal Critical Care. I look forward to leading PCC’s growth strategies to expand our presence.”